As recently as 2018, broadcast networks took in $439 million in ad revenue for its late-night programs. Last year, that number dwindled to $220 million.
Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths were linked to the company’s gene therapies, the Food and Drug Administration said Friday.